-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
-
Summary
-
Kairos Pharma, LTD. quarterly Deferred Tax Assets, Gross history and growth rate from Q4 2023 to Q4 2024.
- Kairos Pharma, LTD. Deferred Tax Assets, Gross for the quarter ending December 31, 2024 was $448K.
Deferred Tax Assets, Gross, Quarterly (USD)